Form 4: Aldeyra Therapeutics Director Martin Joyce Granted Over 71,000 Stock Options

Aldeyra Therapeutics, Inc. director Martin Joseph Joyce was granted 71,655 stock options with an exercise price of $2.685, vesting over one year subject to continued service.

Summary

• Martin Joseph Joyce, a Director of Aldeyra Therapeutics, Inc. (ALDX), was granted a total of 71,655 stock options on June 10, 2025.
• The exercise price for all granted options is $2.685 per share.
• The options include 62,728 shares tied to continuous service as a Board Director, 1,689 shares for service on the Nominating/Corporate Governance Committee, and 7,238 shares for service on the Audit Committee.
• All options are exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided continuous service is maintained through the vesting date.
• The options have an expiration date of June 9, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The grant of stock options is a standard compensation practice that aligns director interests with shareholders, indicating continued commitment. There are no negative financial implications beyond minor potential future dilution.

Positives

• The grant of stock options to Director Martin Joseph Joyce aligns his interests with those of shareholders, incentivizing long-term performance.
• The options are tied to continuous service on the Board and specific committees, reinforcing commitment to corporate governance and oversight.

Negatives

• The issuance of new stock options, if exercised, could lead to a minor dilution of existing shareholders' equity.

Risks

• The value of the stock options is dependent on the future market price of Aldeyra Therapeutics' common stock exceeding the exercise price of $2.685.
• The options' vesting is contingent upon the director's continuous service, meaning they could be forfeited if service is terminated before the vesting date.

Future Outlook

The document does not provide a general future outlook for the company, but the vesting schedule of the options implies a continued commitment from the director for at least one year.

Management Comments

• /s/ Martin Joyce

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically the grant of stock options to a director, which is a common form of executive and director compensation in the biotechnology and pharmaceutical industry to align management incentives with shareholder value.

Corporate Governance

Related Party Transactions

• The grant of stock options to Martin Joseph Joyce, a Director of Aldeyra Therapeutics, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential minor future dilution if options are exercised, but also improved alignment of director's interests with shareholder value.

Next Steps

• The stock options will become exercisable on the one-year anniversary of the grant date (June 10, 2026), provided Martin Joseph Joyce continues his service as a director and committee member.

Key Dates

Keywords

Aldeyra Therapeutics, ALDX, Form 4, SEC filing, stock options, director compensation, insider transaction, equity grant, corporate governance, Martin Joseph Joyce